Milestone! Nine patents exclusively licensed by ShanghaiTech University to Gluetacs Therapeutics have all been granted by the China National Intellectual Property Administration.

ON：2024-03-15 TAG：GLUETACS THERAPEUTICS

Today, China National Intellectual Property Administration officially issued a notice of granting the patent rights for the invention patent application “Immune Modulating Compounds and Their Anti-Tumor Applications” to ShanghaiTech University as the applicant and Dr. Yang Xiaobao, Founder of Gluetacs Therapeutics, as the first inventor. All the 9 patents that ShanghaiTech University exclusively licensed to Gluetacs Therapeutics have been granted successfully. 

Gluetacs’ first pipeline, GT919, originates from a patent license from ShanghaiTech University, and has been transformed by Gluetacs, confirmed for PCC, promoted for clinical applications in both China and the United States, entered Phase I clinical trial, completing the transformation from basic scientific research from 0 to 1. Up to now, Gluetacs has applied for over a hundred patents.